Home
This site is intended for healthcare professionals

Obstructive Sleep Apnea Care Pathways Translating Cardiometabolic Risk into Longitudinal Management: Module 2 Diagnostic Path Activation

Share

Description

This activity is supported by an independent education grant from Lilly. This online education program has been designed for healthcare professionals in the U.S.

In this module, Dr. Somers guides clinicians through translating a positive OSA screen into the correct diagnostic testing pathway. Participants will learn to confidently select home sleep apnea testing (HSAT) for uncomplicated adult cases, while identifying the critical cardiopulmonary, neurological, or comorbidity red flags that strictly necessitate in-lab polysomnography (PSG) or specialist referral.

Session Highlights

  • Apply evidence-based decision algorithms to identify uncomplicated adult patients with a high pre-test probability of moderate-to-severe OSA who are appropriate candidates for home sleep apnea testing (HSAT).
  • Recognize clinical "red flags"—such as significant cardiorespiratory disease, suspected central sleep apnea, chronic opioid use, or a history of stroke—that necessitate referral for in-lab polysomnography (PSG) or specialist evaluation.

Prefer to watch in Spanish? Click Here.

Who Should Participate?

This program is designed for healthcare professionals who seek to incorporate structured OSA screening and diagnostic activation into routine cardiometabolic management workflows.

  • Primary Care Physicians and Family Medicine Practitioners
  • Nurse Practitioners
  • Physician Assistants

This is Module Two of Six, See Modules 1, 3, 4 5 and 6 Here.

Prefer to read? See our Key Clinical Summary Here.

Faculty

Dr Virend Somers

Dr Virend Somers is a Professor of Medicine and Consultant in Preventive Cardiology at Mayo Clinic, and a leading expert in sleep apnea and its cardiovascular consequences. His research focuses on the physiological mechanisms linking obstructive sleep apnea with cardiovascular disease, including changes in autonomic and vascular function, blood pressure, and heart failure. Through his work directing Mayo Clinic’s Sleep Facility, Dr Somers has contributed significantly to understanding how disordered sleep affects cardiovascular health, with a focus on translating these insights into improved recognition, management, and care for patients with sleep apnea.

Disclosures

Partners for Advancing Clinical Education (Partners) requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant financial relationships are mitigated according to Partners policies.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Partners policies. Others involved in the planning of this activity have no relevant financial relationships.

Dr Virend Somers, faculty for this educational activity, has the following relevant financial relationships: Consultant Apnimed, GEM Med, Jazz Pharmaceuticals, Lilly.

The MedAll staff, program planners, and reviewers have no relevant financial relationships with ineligible companies to disclose.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (Partners) and MedAll. Partners is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Education

Partners designates this live activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Associate Continuing Education

Partners has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.25 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 0.25 ANCC contact hours.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Fee Information

There is no fee for this educational activity.

This continuing education activity is active starting September 11th 2026, and will expire on July 1st 2028.

Learning objectives

1: Evaluate the bidirectional relationship between obesity and OSA to inform cardiometabolic risk assessment, demonstrating accurate identification of OSA risk within ≥75% of post-activity case-based assessments.

2: Identify patients at increased risk of OSA using clinical features and comorbidities in primary care, achieving appropriate risk stratification in ≥75% of applied clinical scenarios.

3: Apply workflow-compatible screening and triage strategies to support early identification of OSA, demonstrating correct use of structured tools and decision pathways in ≥75% of simulation-based exercises.

4: Select appropriate diagnostic and referral pathways, including HSAT, based on clinical presentation and practice context, achieving appropriate pathway activation in ≥75% of case-based assessments.

5: Apply longitudinal management and treatment progression strategies in OSA care planning to support sustained disease control, demonstrating appropriate decision-making in ≥70% of longitudinal case exercises.

6: Apply contextually adapted care strategies that account for socioeconomic and practice-setting factors to support equitable diagnostic and management decisions in OSA, demonstrating appropriate decision-making in ≥70% of applied scenarios.

Similar communities

View all

Similar events and on demand videos

Computer generated transcript

Warning!
The following transcript was generated automatically from the content and has not been checked or corrected manually.

Now we're going to cover the section on diagnostic path activation. Who is an appropriate home sleep apnea testing candidate? And here we we uh abbreviate home sleep apnea testing with HSAT. Now, HSAT may be appropriate when you've got an adult patient with a high pre-test probability of moderate to severe obstructive sleep apnea, and there's no major comorbidities that could complicate home test interpretation. The patient can complete the test at home with appropriate instructions and support. And follow up is in place to review results and activate treatment if indeed sleep apnea is confirmed now. Use a polysomnogram, an overnight in-hospital polysomnogram, and go through a specialist sleep clinician pathway instead, if there is significant cardiorespiratory disease, for example, very severe, um, chronic obstructive airway disease. Uh, and suspected central sleep apnea or hyperventilation should prompt an in-hospital study if there's neuromuscular weakness, chronic opioid use, history of stroke, or severe insomnia. And if You had a high suspicion of obstructive sleep apnea, but the home sleep apnea test was negative, inconclusive, or technically inadequate. In that case, for sure, go on to have a monitored in lab, uh, sleep study to more clearly exclude or confirm the diagnosis of obstructive sleep apnea. Now, when do we refer for in-lab PSG or specialist assessment? This set of uh flow diagrams show, first, The home sleep apnea testing pathway fit that would be an adult patient with a high pre-test probability of moderate to severe sleep apnea, uncomplicated clinical profile, able to complete the home test with instructions and support, and follow-up is arranged for result review, but check the context first. Is there a local diagnostic pathway? What are the payer requirements? Is an occupational safety sensitive role. Borderline comorbidities or uncertain symptoms is access or support needed to complete testing and go on to use a polysomnogram or referral to a sleep specialist if there is, as I mentioned earlier, significant cardiorespiratory disease, suspected central sleep apnea, or hyperventilation, including obesity, hyperventilation syndrome, neuromuscular weakness, or chronic opioid use. History of stroke or severe insomnia, negative, inconclusive, or technically inadequate home sleep apnea testing with continued suspicion of obstructive sleep apnea. A positive screen should trigger pathway selection with home sleep apnea testing preferred, if appropriate, in uncomplicated presentations. Now, here's the decision algorithm. Screen positive. Now what? You've got a positive OSA screen or a clinical suspicion. You go to a comprehensive sleep evaluation. You look at symptoms, comorbidities, medication risks, sleep history, red flags to say maybe not a home sleep apnea test. That's significant cardiorespiratory disease, suspected central apnea, hyperventilation, neuromuscular weakness, chronic opioids, stroke history, severe insomnia. If any of those are yes, go for a polysomnogram and a specialist assessment. If no, go to an uncomplicated, lower cost. Tests like a home sleep apnea test in adults with high pre-test probability, but make sure that the home sleep apnea test is appropriate for the patient and also available. Now, let's go back to Mr. R. When does a positive screen become a test order? So, Mr. R has hypertension and type 2 diabetes. He's got no significant cardiopulmonary disease or suspected central sleep apnea. He's got an elevated stop bang score. He's got symptoms and risk factors consistent with high OSA risk, including falling asleep in inappropriate situations and disruptive snoring. Decision rationale, uncomplicated high-risk adult home sleep apnea testing is an appropriate pathway where available. Action is order the HSAT, explain to the patient and the spouse what the test involves, and schedule schedule follow-up to review results, the latter being also very, very important. Remember, the clinical reasoning here, this is not a patient. I will simply tell to lose weight and revisit later. A positive screen plus this risk profile absolutely needs diagnostic confirmation. So, if your home sleep apnea testing is negative in a patient with hypertension, diabetes, obesity, sleepiness, disruptive snoring, You should really worry about, about obstructive sleep apnea. And so, if for some reason the HSAT is not positive, go on to referral to a sleep clinic and sleep specialist for an in-hospital polysomnogram. Now, let's go to this polling question. How confident are you selecting between home sleep apnea tests and a specialist referral for a patient with suspected OSA based on the criteria that we talked about earlier? A, very confident. B, somewhat confident. C, not very confident. D, not at all confident. And we'll wait while you plug in your answer. This is a summary checklist showing the key practice points from this particular phase. First, recognize that screening tools do not diagnose OSA alone. Identify uncomplicated adults who may be appropriate for home sleep apnea testing. Identify complexity signals that favor polysomnogram or a specialist referral. Avoid letting diagnostic uncertainty become diagnostic delay. And document pathway choice and rationale.